This trial involved the aerosolized delivery of AAT to CF patients and found a significant reduction in NE, IL-8, IL-1β, and TNF-α levels after 4 weeks of treatment in comparison to baseline; however no increase in FEV1 was observed [112]. Here, IL1B is linked to cystic fibrosis.